Vascular access device type for systemic anti-cancer therapies in cancer patients: A scoping review

• Published in: Critical reviews in oncology/hematology Vol. 196; p. 104277
• Main Authors: Duggan, C., Hernon, O., Dunne, R., McInerney, V., Walsh, S.R., Lowery, A., McCarthy, M., Carr, P.J.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.04.2024
• Subjects: Anti-cancer drugs; Central venous access device; Chemotherapy; Intravenous; Peripheral intravenous cannulation; Systemic; Vascular access device; Chemotherapy; Peripheral intravenous cannulation; Intravenous; Anti-cancer drugs; Vascular access device; Central venous access device; Systemic
• ISSN: 1040-8428; 1879-0461; 1879-0461
• DOI: 10.1016/j.critrevonc.2024.104277

Patients with cancer can expect to receive numerous invasive vascular access procedures for intravenous therapy and clinical diagnostics. Due to the increased incidence and prevalence of cancer globally there will be significantly more people who require first-line intravenous chemotherapy over the next ten years. Our objective was to determine the types of evidence that exist for the vascular access device (VAD) type for the delivery of systemic anti-cancer therapy (SACT) in cancer patients. We used JBI scoping review methodology to identify the types of VADs used for SACT and with a specific search strategy included articles from 2012–2022 published in the English language. We identify (i) type of VADs used for SACT delivery (ii) the type of insertion and post-insertion complications (iii) the geographical location and clinical environment (iv) and whether VAD choice impacts on quality of life (QOL). Findings were presented using the PAGER framework. Our search strategy identified 10,390 titles, of these, 5318 duplicates were removed. The remaining 5072 sources were screened for eligibility, 240 articles met the inclusion criteria. The most common design include retrospective study designs (n = 91) followed by prospective study designs (n = 31). We found 28 interventional studies with 21 registered in a clinical trial registry and identified no core outcome sets papers specific to VAD for SACT. The most prevalent publications were those that featured two or more VAD types (n = 70), followed by tunnelled intravenous VADs (n = 67). Of 38 unique complications identified, the most frequent catheter related complication was catheter related thrombosis (n = 178, 74%), followed by infection (n = 170, 71%). The county where the most publications originated from was China (n = 62) with one randomized controlled multicenter study from a comprehensive cancer centre. Of the thirty three studies that included QOL we found 4 which reported on body image. No QOL measurement tools specific to the process of SACT administration via VAD are available Our findings suggest a systematic review and meta-analysis of VAD use for intravenous SACT can be considered. However, the development of a core outcome set for SACT should be prioritised. Funding for high quality programs of research for VAD in cancer are needed. Comprehensive cancer centres should lead this research agenda. [Display omitted] •Catheter-related thrombosis was the most common catheter related complication, followed by infection.•Publications that included two or more VAD types were the most common.•Insufficient studies have been done on clinical competency and education around vascular access devices and systemic anti-cancer therapy.•Current medical device technologies and health service procedures involving VADs and SACT need to be improved due to the volume of issues they cause.•To support the most optimal VAD for SACT, more interventional studies and/or clinical registries are required.